The introduction of anti-VEGF agents has revolutionized the field of medical retina care by reducing rates of vision loss and ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) today announced newly ...

Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

Why should we be interested in affordable stocks? Some investors like to look for cheaper stocks in order to diversify their ...

A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and ...

Researchers at McMaster University have made a discovery in the field of hematology, providing an explanation for spontaneous ...

PROVIDENCE, RI - Ocean Biomedical (NASDAQ: OCEA) has announced research findings that show its immunotherapy candidates can work synergistically with tyrosine kinase inhibitors (TKIs), potentially ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with full-dose ...

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, with disease progression ranging from slow and indolent to aggressive ...